Kyowa Kirin, a Tokyo-based bio/pharmaceutical company, has completed the construction of a new JPY 16.8-billion ($118-million) biologics drug-substance manufacturing facility at its site in Takasaki, Japan. The GMP facility will include manufacturing for early-phase development and a pilot facility for process development. In addition, a training facility for the manufacturing and quality control of biopharmaceuticals has been set up in the facility.  

The facility is part of the company’s plan to increase in-house drug-substance manufacturing. Last year (2024), the company began construction of a new $530-million biomanufacturing facility in Sanford, North Carolina. The 171,700-square-foot facility is scheduled to be completed in 2027.  

The Sanford facility will round out Kyowa Kirin’s global manufacturing network, which includes two sites in Japan, the one in Takasaki and another in Ube City. The Sanford, North Carolina, facility will be the company’s first manufacturing facility in the US.    

Source: Kyowa Kirin